Your browser doesn't support javascript.
loading
A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination.
Shimada, Yoshitaka; Nagaba, Yasushi; Okawa, Hiroyuki; Ehara, Kaori; Okada, Shinya; Yokomori, Hiroaki.
Afiliación
  • Shimada Y; Department of Internal Medicine, Kitasato University Medical Center, Saitama, Japan.
  • Nagaba Y; Department of Internal Medicine, Kitasato University Medical Center, Saitama, Japan.
  • Okawa H; Department of Internal Medicine, Kitasato University Medical Center, Saitama, Japan.
  • Ehara K; Department of Internal Medicine, Kitasato University Medical Center, Saitama, Japan.
  • Okada S; Division of Pathology, Kitasato University Medical Center, Saitama, Japan.
  • Yokomori H; Department of Internal Medicine, Kitasato University Medical Center, Saitama, Japan.
Medicine (Baltimore) ; 101(43): e31304, 2022 Oct 28.
Article en En | MEDLINE | ID: mdl-36316859
RATIONALE: Coronavirus disease (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 virus, was reported in Wuhan of China in December 2019. The world is still in a state of pandemic owing to COVID-19. COVID-19 vaccines help our bodies develop immunity against the virus that causes COVID-19 without having to get the illness. Herein, we describe a rare case of a critical disorder, hemophagocytic lymphohistiocytosis (HLH), in a patient with nephritic sclerosis associated with hypertension, following mRNA COVID-19 vaccination. HLH is a life-threatening hyperinflammatory syndrome caused by aberrantly activated macrophages and cytotoxic T cells that may rapidly progress to terminal multiple organ failure. PATIENT CONCERNS: An 85-year-old Japanese woman with chronic renal failure and hypertension was included in this study. Routine laboratory investigations provided the following results: white blood cell (WBC) count, 4.6 × 109/L; hemoglobin (Hb), 8.1 g/dL; platelet count, 27 × 109/L; blood urea nitrogen 48.9 mg/dL, and serum creatinine 3.95 mg/dL. The patient developed malaise, vomiting, and persistent high fever (up to 39.7°C) on the 12th day after receiving the second dose of the vaccine. Initial evaluation revealed neutropenia. The total WBC count was 0.40 × 109/L (Neutrophils 0, Lymphocytes 240/µ, blast 0%); Hb 9.0 g/dL, platelet count 27 × 109/L; and, C Reactive Protein 9.64 mg/dL. DIAGNOSIS: Further tests showed hyperferritinemia (serum ferritin 2284.4 µg/L). Bone marrow examination revealed haemophagocytosis. A provisional diagnosis of HLH associated with the Comirnaty® vaccination was made based on the HLH-2004 diagnostic criteria. INTERVENTIONS: The patient was treated with granulocyte colony-stimulating factor and 500 mg methylprednisolone. OUTCOMES: A significant improvement was observed in the patient's condition; the abnormal laboratory results resolved gradually, and the patient was discharged. LESSONS: This case serves to create awareness among clinicians that HLH is a rare complication of COVID-19 vaccination and should be considered, especially in patients with a history of chronic renal failure and hypertension.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfohistiocitosis Hemofagocítica / Vacunas contra la COVID-19 / COVID-19 / Hipertensión / Fallo Renal Crónico Tipo de estudio: Diagnostic_studies Límite: Aged80 / Female / Humans Idioma: En Revista: Medicine (Baltimore) Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfohistiocitosis Hemofagocítica / Vacunas contra la COVID-19 / COVID-19 / Hipertensión / Fallo Renal Crónico Tipo de estudio: Diagnostic_studies Límite: Aged80 / Female / Humans Idioma: En Revista: Medicine (Baltimore) Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos